|
US2021059962A1
|
|
Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunity
|
|
WO2019104199A1
|
|
Small molecule agonists and antagonists of nr2f6 activity
|
|
US2018346456A1
|
|
Small molecule agonists and antagonists of nr2f6 activity
|
|
US2018214413A1
|
|
Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
|
|
US2017304418A1
|
|
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
|
|
US2017362596A1
|
|
Methods and means of generating il-17 associated antitumor effector cells by inhibition of nr2f6 inhibition
|
|
US2019358224A1
|
|
Small molecule modulators of nr2f6 activity
|
|
US2017166896A1
|
|
Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing Agents
|
|
US2017246207A1
|
|
Antigen specific mrna cellular cancer vaccines
|
|
US2016151469A1
|
|
Immune modulation by tlr activation for treatment of filovirus infections including ebola
|
|
US2016074489A1
|
|
Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
|
|
US2016025746A1
|
|
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
|
|
US2014065096A1
|
|
Cancer therapy by ex vivo activated autologous immune cells
|
|
US2015037303A1
|
|
Cells, compositions, and treatment methods for stimulation of hematopoiesis
|
|
US2013309210A1
|
|
Acceleration of hematopoietic reconstitution by placental endothelial and endothelial progenitor cells
|
